068760.KS KSC
Celltrion Pharm Inc
1W: -3.6%
1M: -19.4%
3M: -6.4%
1Y: +0.5%
3Y: -7.5%
5Y: +0.4%
₩93,500.00
Last traded 2024-08-14 — delisted
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
#?
of ?
Drug Manufacturers - Specialty & Generic
Technical Signal Map
3 Bullish
3 Neutral
7 Bearish
068760.KS
—
Celltrion Pharm Inc
N/A
0
128940.KS
$6.3T
Hanmi Pharm. Co., Ltd.
BULLISH
+69
000640.KS
$642B
Dong-A Socio Holdings Co., Ltd.
BULLISH
+59
047920.KQ
$366B
HLB Pharmaceutical Co., Ltd
LEAN BULL
+19
019175.KS
$375B
Shinpoong Pharmaceutical Co.,Ltd
NEUTRAL
+1
003000.KS
$410B
Bukwang Pharmaceutical Co., Ltd.
NEUTRAL
-7
019170.KS
$485B
Shinpoong Pharmaceutical Co., Ltd.
LEAN BEAR
-26
001060.KS
$627B
JW Pharmaceutical Corporation
BEARISH
-50
249420.KS
$459B
Ildong Pharmaceutical Co., Ltd.
BEARISH
-50
003090.KS
$655B
Daewoong Co., Ltd.
BEARISH
-66
068760.KQ
$1.8T
Celltrion Pharm, Inc.
BEARISH
-82
069620.KS
$1.3T
Daewoong pharmaceutical Co.,Ltd
BEARISH
-82
000100.KS
$5.6T
Yuhan Corporation
BEARISH
-91
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| 068760.KS Celltrion Pharm Inc | — | 39.5 | 8.2 | 8.3 | 5.8 | 23.6 | 8 | N/A | 0.5 |
| 128940.KS Hanmi Pharm. Co., Ltd. | $6.3T | 27.3 | 17.1 | 16.2 | 17.8 | 12.9 | 9 | BULLISH | 81.4 |
| 000640.KS Dong-A Socio Holdings Co., Ltd. | $642B | 7.6 | 7.4 | 6.5 | 7.1 | 10.1 | 6 | BULLISH | -15.8 |
| 047920.KQ HLB Pharmaceutical Co., Ltd | $366B | 119.0 | 2.2 | 1.3 | -0.1 | 68.6 | 4 | LEAN BULL | -33.5 |
| 019175.KS Shinpoong Pharmaceutical Co.,Ltd | $375B | -968.6 | -0.3 | -131.2 | -12.5 | 6.2 | 6 | NEUTRAL | -44.1 |
| 003000.KS Bukwang Pharmaceutical Co., Ltd. | $410B | 67.9 | 3.0 | 4.8 | 2.5 | 20.1 | 5 | NEUTRAL | 21.4 |
| 019170.KS Shinpoong Pharmaceutical Co., Ltd. | $485B | -968.6 | -0.3 | -131.2 | -12.5 | 6.2 | 6 | LEAN BEAR | -33.1 |
| 001060.KS JW Pharmaceutical Corporation | $627B | 6.4 | 27.6 | 23.8 | 12.6 | 10.4 | 7 | BEARISH | 20.2 |
| 249420.KS Ildong Pharmaceutical Co., Ltd. | $459B | 10.2 | 20.7 | 6.3 | 3.9 | -0.7 | 7 | BEARISH | -30.6 |
| 003090.KS Daewoong Co., Ltd. | $655B | 3.3 | 15.6 | 11.5 | 6.0 | 4.6 | 4 | BEARISH | -30.9 |
| 068760.KQ Celltrion Pharm, Inc. | $1.8T | 39.5 | 9.9 | 9.8 | 9.0 | 13.9 | 8 | BEARISH | -27.4 |
| 069620.KS Daewoong pharmaceutical Co.,Ltd | $1.3T | 6.4 | 20.6 | 10.3 | 7.4 | 9.9 | 4 | BEARISH | -18.7 |
| 000100.KS Yuhan Corporation | $5.6T | 25.9 | 10.4 | 4.4 | 11.0 | 5.4 | 7 | BEARISH | -33.8 |
| 068760.KS Celltrion Pharm Inc | — | 39.5 | 8.2 | 8.3 | 5.8 | 23.6 | 8 | N/A | 0.5 |
| 128940.KS Hanmi Pharm. Co., Ltd. | $6.3T | 27.3 | 17.1 | 16.2 | 17.8 | 12.9 | 9 | BULLISH | 81.4 |
| 000640.KS Dong-A Socio Holdings Co., Ltd. | $642B | 7.6 | 7.4 | 6.5 | 7.1 | 10.1 | 6 | BULLISH | -15.8 |
| 047920.KQ HLB Pharmaceutical Co., Ltd | $366B | 119.0 | 2.2 | 1.3 | -0.1 | 68.6 | 4 | LEAN BULL | -33.5 |
| 019175.KS Shinpoong Pharmaceutical Co.,Ltd | $375B | -968.6 | -0.3 | -131.2 | -12.5 | 6.2 | 6 | NEUTRAL | -44.1 |
| 003000.KS Bukwang Pharmaceutical Co., Ltd. | $410B | 67.9 | 3.0 | 4.8 | 2.5 | 20.1 | 5 | NEUTRAL | 21.4 |
| 019170.KS Shinpoong Pharmaceutical Co., Ltd. | $485B | -968.6 | -0.3 | -131.2 | -12.5 | 6.2 | 6 | LEAN BEAR | -33.1 |
| 001060.KS JW Pharmaceutical Corporation | $627B | 6.4 | 27.6 | 23.8 | 12.6 | 10.4 | 7 | BEARISH | 20.2 |
| 249420.KS Ildong Pharmaceutical Co., Ltd. | $459B | 10.2 | 20.7 | 6.3 | 3.9 | -0.7 | 7 | BEARISH | -30.6 |
| 003090.KS Daewoong Co., Ltd. | $655B | 3.3 | 15.6 | 11.5 | 6.0 | 4.6 | 4 | BEARISH | -30.9 |
| 068760.KQ Celltrion Pharm, Inc. | $1.8T | 39.5 | 9.9 | 9.8 | 9.0 | 13.9 | 8 | BEARISH | -27.4 |
| 069620.KS Daewoong pharmaceutical Co.,Ltd | $1.3T | 6.4 | 20.6 | 10.3 | 7.4 | 9.9 | 4 | BEARISH | -18.7 |
| 000100.KS Yuhan Corporation | $5.6T | 25.9 | 10.4 | 4.4 | 11.0 | 5.4 | 7 | BEARISH | -33.8 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
068760.KS vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F